Showing results (3311-3320 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|June 19, 2002
Lipid formulation as a drug carrier for drug deliveryYoshifumi TomiiCurrent Pharmaceutical Design|July 27, 2001
Role of dendritic cell-derived cytokines in immune regulationY Wan, J BramsonCurrent Pharmaceutical Design|July 27, 2001
Trypanothione as a target in the design of antitrypanosomal and antileishmanial agentsK Augustyns, K Amssoms, A Yamani, et al.Current Pharmaceutical Design|July 27, 2001
The epothilones, eleutherobins, and related types of moleculesS J Stachel, K Biswas, S J DanishefskyCurrent Pharmaceutical Design|July 27, 2001
Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic controlC Weyer, D G Maggs, A A Young, et al.Current Pharmaceutical Design|July 27, 2001
Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetesD J DruckerCurrent Pharmaceutical Design|July 27, 2001
Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?N G Morgan, S L ChanCurrent Pharmaceutical Design|September 1, 2001
Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapyJ G McCormack, N Westergaard, M Kristiansen, et al.Current Pharmaceutical Design|April 8, 2003
Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiersU K Buchwald, L PirofskiCurrent Pharmaceutical Design|April 8, 2003
The application of information technology to regional, national, and global surveillance of antimicrobial resistanceDaniel F Sahm, Clyde Thornsberry, James A KarlowskyPageof 1,008